Details of the Drug Combination

General Information of Drug Combination (ID: DCGCS6W)

• Drug Combination Name: GDC-0084 + Eltanexor oral
• Indication: Ewing sarcoma; Status: Investigative [1]
• Component Drugs:
  GDC-0084 (DMA9SEY): N.A.
  Eltanexor oral (DM7CLEZ): N.A.
• High-throughput Screening Result:
  Testing Cell Line: TC-71
  Zero Interaction Potency (ZIP) Score: 2.82
  Bliss Independence Score: 2.353
  Loewe Additivity Score: 1.327
  LHighest Single Agent (HSA) Score: 1.932

Molecular Interaction Atlas of This Drug Combination

Indication(s) of GDC-0084

Disease Entry	ICD 11	Status	REF
Glioblastoma of brain	2A00.00	Phase 2	[2]

GDC-0084 Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
PI3-kinase gamma (PIK3CG)	TTHBTOP	PK3CG_HUMAN	Inhibitor	[4]

Indication(s) of Eltanexor oral

Disease Entry	ICD 11	Status	REF
Colorectal cancer	2B91.Z	Phase 1/2	[3]
Myelodysplastic syndrome	2A37	Phase 1/2	[3]
Prostate cancer	2C82.0	Phase 1/2	[3]

Eltanexor oral Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Exportin-1 (XPO1)	TTCJUR4	XPO1_HUMAN	Inhibitor	[3]

References

• [1] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [2] ClinicalTrials.gov (NCT03522298) Safety, Pharmacokinetics and Efficacy of Paxalisib (GDC-0084) in Newly-diagnosed Glioblastoma. U.S. National Institutes of Health.
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] Current clinical development of PI3K pathway inhibitors in glioblastoma. Neuro Oncol. 2012 July; 14(7): 819-829.